TW
BIIB icon

TrinityPoint Wealth’s Biogen BIIB Stock Holding History

TrinityPoint Wealth’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,368
Closed -$820K – 305
2021
Q2 		$820K Sell
2,368
-362
-13% -$110K 0.17% 125
2021
Q1 		$764K Buy
2,730
+278
+11% +$75K 0.18% 121
2020
Q4 		$666K Sell
2,452
-182
-7% -$47K 0.16% 122
2020
Q3 		$747K Buy
2,634
+69
+3% +$19.2K 0.21% 111
2020
Q2 		$686K Sell
2,565
-95
-4% -$28.6K 0.22% 105
2020
Q1 		$841K Buy
2,660
+69
+3% +$20.9K 0.33% 84
2019
Q4 		$769K Sell
2,591
-754
-23% -$209K 0.26% 100
2019
Q3 		$982K Buy
+3,345
New +$779K 0.34% 77
2019
Q2 		– Sell
-3,633
Closed -$859K – 172
2019
Q1 		$859K Buy
3,633
+621
+21% +$196K 0.42% 68
2018
Q4 		$906K Buy
+3,012
New +$961K 0.56% 50

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TrinityPoint Wealth's BIIB Position: Q3 2021 in Review

TrinityPoint Wealth sold out of Biogen (BIIB) in Q3 2021, closing a stake of 2,368 shares — an estimated $820K sold.

TrinityPoint Wealth first reported a position in BIIB in Q4 2018 and held it in 10 quarters. The position peaked at $982K in Q3 2019. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

  • TrinityPoint Wealth reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
  • TrinityPoint Wealth sold 2,368 Biogen shares in Q3 2021, an estimated $820K.
  • TrinityPoint Wealth first reported a position in Biogen in Q4 2018 and held it in 10 quarters.
  • TrinityPoint Wealth's Biogen position peaked at $982K in Q3 2019.
  • 1,041 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on TrinityPoint Wealth's 13F filing for Q3 2021, filed 12 Nov 2021.